Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors

ClinicalTrials.gov ID: NCT01522820

Public ClinicalTrials.gov record NCT01522820. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 21, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I Clinical Trial of mTOR Inhibition With Rapamycin for Enhancing Intranodal Dendritic Cell Vaccine Induced Anti-tumor Immunity in Patients With NY-ESO-1 Expressing Solid Tumors

Study identification

NCT ID: NCT01522820
Recruitment status: Completed
Study type: Interventional
Phase: Phase 1
Lead sponsor: Roswell Park Cancer Institute; Other
Enrollment: 18 participants

Conditions and interventions

Conditions

Interventions

DEC-205/NY-ESO-1 Fusion Protein CDX-1401 Biological
Laboratory Biomarker Analysis Other
Pharmacological Study Other
Sirolimus Drug

Biological · Other · Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Feb 29, 2012
Primary completion: Jun 30, 2016
Completion: Jun 30, 2016
Last update posted: Oct 3, 2016

2012 – 2016

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Roswell Park Cancer Institute	Buffalo	New York	14263	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01522820, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 3, 2016 · Synced May 21, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01522820 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →